All In Biotech

Drug Trial Radar · NCT04956640

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Jul 19, 2021

Primary completion

Apr 2027

Study completion Apr 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.

Conditions

  • Carcinoma, Non-Small-Cell Lung
  • Colorectal Neoplasms
  • Endometrial Neoplasms
  • Ovarian Neoplasms
  • Pancreatic Neoplasms
  • Biliary Tract Neoplasms

Interventions

  • LY3537982Drug

    Oral

  • PembrolizumabDrug

    Intravenous

  • CetuximabDrug

    Intravenous

  • PemetrexedDrug

    Intravenous

  • CisplatinDrug

    Intravenous

  • CarboplatinDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapyTime frame: Cycle 1 (21 Days)
  2. Phase 1b: To assess the safety and tolerability of LY3537982 when administered alone or in combination with other investigational agentsTime frame: Cycle 1 (21 Days)
  3. Phase 1b: To determine the optimal dose of LY3537982 to be administered to treatment-naïve participants with advanced NSCLC in combination with pembrolizumabTime frame: Estimated up to 2 years
  4. To determine the optimal dose of LY3537982 to be administered to participants who have received at least one prior oxaliplatin- or irinotecan-containing regimen for advanced or metastatic CRC in combination with cetuximabTime frame: Estimated up to 2 years
  5. To assess the antitumor activity of LY3537982 monotherapy in participants with advanced pancreatic cancer with KRAS G12C mutationTime frame: Estimated up to 2 years

Locations

49 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • USC Norris Cancer Hospital

    Los Angeles, California

  • Chao Family Comprehensive Cancer Ctr.

    Orange, California

  • Yale-New Haven Hospital

    New Haven, Connecticut

  • AdventHealth Orlando

    Orlando, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • Indiana Univ Melvin & Bren Simon Cancer Center

    Indianapolis, Indiana

  • Community Health Network

    Indianapolis, Indiana

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • NYU Langone Health- Long Island

    Mineola, New York

  • NYU Langone

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • The University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Novant Health Cancer Institute - Elizabeth

    Charlotte, North Carolina

  • Novant Health Cancer Institute - Forsyth

    Winston-Salem, North Carolina

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • Vanderbilt Univeristy School of Medicine

    Nashville, Tennessee

  • South Texas Accelerated Research Therapeutics (START)

    San Antonio, Texas

  • START Mountain Region

    West Valley City, Utah

  • Inova Health System IRB

    Fairfax, Virginia

  • USO-Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • University of Wisconsin-Madison Hospital and Health Clinic

    Madison, Wisconsin

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • St Vincent's Hospital Sydney

    Sydney, New South Wales, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Peninsula and Southeast Oncology

    Frankston, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Princess Margaret Hospital (Ontario)

    Toronto, Ontario, Canada

  • Institut du Cancer de Montpellier - Val d'aurelle

    Montpellier, France

  • Institut Claudius Regaud - IUCT Oncopole

    Toulouse, France

  • Gustave Roussy

    Villejuif, France

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

    Bordeaux, Aquitaine, France

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, France

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.